UntilLabs

San Francisco, CA Biotechnology Private

Until (formerly Cradle Healthcare) is a San Francisco-based biotechnology company building medical infrastructure to pause biological time. The company develops perfusion hardware, cryoprotective agents, and rewarming infrastructure to reversibly cryopreserve biological systems. Its initial focus is organ-scale reversible cryopreservation, which entails preserving donor organs at temperatures compatible with indefinite storage and then rewarming them for transplant, addressing logistical bottlenecks in the organ transplant supply chain. Its longer-term vision is whole-body medical hibernation technology. Co-founded by venture capitalist and longevity pioneer Laura Deming (CEO) and chief scientist Hunter Davis, Until emerged from three years of stealth as Cradle in mid-2024 with $48M in seed funding and rebranded to Until ahead of its $58M Series A in September 2025, led by Founders Fund with participation from Lux Capital and Field Ventures.

Overview

Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Founded

2021

Employees

11–50

Total Funding

$106M

2 rounds

Funding

Total raised $106M across 2 rounds

Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Last updated 06-25-2026

Latest Round

Type

Series A

Date

September 22, 2025

Amount

$58M

Valuation

Lead Investors

Founders Fund
DateRoundAmount RaisedValuationLead Investors
September 22, 2025 Series A $58M Founders Fund
2024 Seed $48M Not disclosed

Leadership

  • Laura Deming

    Co-Founder & CEO

    LinkedIn
  • Hunter Davis

    Co-Founder & Chief Scientist

Competitors

Competitor list is illustrative and may be incomplete, stale, or erroneous.

  • X-Therma

    Berkeley-based biotech developing biomimetic cryoprotectants and the THERMAGUARD organ preservation platform for sub-zero, ice-free organ storage to extend transplant viability windows.

  • Sylvatica Biotech

    North Charleston, SC startup developing supercooling and partial-freezing technologies to preserve organs and tissues for transplant beyond conventional cold storage limits.

  • TransMedics

    Public (Nasdaq: TMDX) organ care company commercializing normothermic ex-vivo organ perfusion (OCS) systems for heart, lung, and liver transplantation; a market-leading alternative-preservation peer to cryopreservation entrants.

  • XVIVO Perfusion

    Swedish public organ preservation and perfusion company providing solutions and machine perfusion systems used by transplant centers globally.

  • Paragonix Technologies

    US developer of FDA-cleared organ transportation and hypothermic preservation devices for heart, lung, kidney, liver, and pancreas; acquired by Getinge in 2024.

  • Tomorrow Bio

    Berlin-based human cryopreservation provider focused on whole-body cryonics after legal death, representing the adjacent whole-body hibernation vision Until is pursuing scientifically.

UntilLabs Investment FAQ

Public status and buying access

No. UntilLabs is a private company and does not have a public stock ticker or trade on a public stock exchange. Its shares are generally held by founders, employees, investors, and other private shareholders. Buyers and sellers may be able to transact in UntilLabs shares through private secondary transactions, but any transaction depends on share availability, buyer and seller agreement, transfer restrictions, company approval rights, and any applicable right of first refusal. There is no guarantee that UntilLabs will complete an IPO or other liquidity event.

Yes, it is sometimes possible to buy UntilLabs shares pre-IPO through private secondary transactions. This depends on finding a willing seller, company approval, and satisfying any transfer restrictions or rights of first refusal.

Buyers interested in buying UntilLabs shares on the secondary market typically do so through SetterVC and other secondary-market platforms, subject to eligibility requirements, share availability, transfer restrictions, and issuer approval. Buyers may need to satisfy sophistication, accreditation, institutional, platform, regulatory, or other eligibility requirements before participating. Once eligible, buyers may be able to view listings, make bids, and work with a licensed broker through the transaction process. Buyers should ensure they have appropriate legal and financial advisors guiding them before completing any transaction.

Valuation and funding

UntilLabs's latest disclosed funding round was a Series A round in September 22, 2025. The round raised approximately $58M, with Founders Fund listed as disclosed lead or major investors. Primary funding rounds are different from secondary transactions: in a primary round, capital goes to the company, while in a secondary transaction, investors buy existing shares from current shareholders. Funding-round data reflects publicly reported or collected information and may be incomplete.

UntilLabs has raised approximately $106M in disclosed funding across 2 rounds. These figures reflect primary capital raised by the company and do not include every possible secondary transaction, undisclosed round, debt facility, or private transfer. Reported funding totals can change as new rounds are announced or older round details are corrected. Eligible users can use SetterVC to track UntilLabs's funding history alongside private-market activity where available.

UntilLabs's disclosed investors include Founders Fund. Investor lists are based on public reporting, company announcements, and collected funding-round data, and may be incomplete. Participation in a prior funding round does not mean those investors are currently buying or selling shares. On SetterVC, eligible users can review UntilLabs's funding history, valuation history, and private-market activity alongside other venture-backed companies.

Market context

UntilLabs's most-cited competitors include X-Therma, Sylvatica Biotech, TransMedics, XVIVO Perfusion, Paragonix Technologies and Tomorrow Bio. Investors often compare these companies by sector, product focus, valuation, funding raised, growth signals, investor base, and private-market activity.

Secondary-market demand for UntilLabs shares can be affected by company performance, revenue growth, profitability, funding history, valuation, investor interest, sector momentum, public-market conditions, expected timing of a liquidity event, and the availability of shares for sale. Demand can also be affected by transfer restrictions, company approval rights, right of first refusal processes, limited information, and the price expectations of buyers and sellers. Strong demand does not guarantee strong pricing, liquidity, or investment returns. Weak demand does not necessarily reflect the company's long-term prospects. Demand signals should not be treated as a recommendation or prediction of investment performance. Buyers and sellers should treat demand signals as informational and conduct their own diligence before transacting.

Selling and transaction mechanics

Sellers often rely on intermediaries and platforms, such as SetterVC and other secondary-market platforms, to identify potential buyers. The exact process varies by company and transaction, but sellers often begin by confirming their ownership, desired price, transferability, and any company approval or notice requirements. If the seller agrees with a buyer on acceptable price and terms, the company may need to be notified through a share transfer notice or similar process. If a right of first refusal, company approval right, or other transfer restriction applies, the seller may need to wait until that process is completed. The parties may then execute a purchase and sale agreement, complete required transfer documentation, and close if all required conditions are satisfied. Sellers should always seek proper legal and financial advice before completing the transaction.

Yes, current and former UntilLabs employees, early investors, and other existing shareholders may be able to sell vested shares before an IPO through a private secondary sale. This is not automatic; it depends on whether the shareholder has transferable shares, whether there is buyer demand, and whether the company's governing documents permit the transfer. Many companies require prior notice, company approval, or a right of first refusal before shares can be sold. Sellers should also seek proper legal and financial advice before proceeding.

A UntilLabs secondary transaction usually involves an existing shareholder selling shares to a buyer before a public listing. The buyer and seller typically agree on price, number of shares, share class, and closing conditions. The seller may then need to notify UntilLabs through a share transfer notice or similar process. If UntilLabs or existing investors have approval rights, transfer restrictions, or a right of first refusal, those steps may need to be completed before the transfer can close. The parties typically enter into a purchase and sale agreement, complete any required transfer documentation, and close only if the necessary conditions are satisfied. Timing and certainty can vary by company and transaction.

In most private secondary transactions, parties commonly use a purchase and sale agreement that outlines price, terms, and conditions. They may also use share transfer documentation, often a stock transfer notice, share transfer notice, transfer instruction, or similar document, along with any required company approval or right of first refusal materials. Proof of ownership, such as a cap table entry, share certificate, brokerage statement, issuer confirmation, or administrator confirmation, may also be important. Buyers often request recent company financials, but private companies may limit disclosure. Since every deal varies, buyers and sellers should consult legal and financial advisors to understand which documents are needed.

Risk, diligence, and investor caution

Buying UntilLabs shares pre-IPO is risky. Shares are illiquid, no IPO or liquidity event is guaranteed, valuations can change, transfers may require company approval, and private companies may provide limited financial disclosure. Be prepared for total loss. SetterVC and Setter Capital do not provide due diligence, legal, tax, accounting, valuation, or investment advice. Buyers must conduct their own due diligence, verify information, and seek independent legal and investment advice before proceeding.

Private secondary shares are typically illiquid. Unlike public stocks, there is no active public market, so selling them can be difficult and time-consuming. Sales depend on finding a willing buyer and often require company approval. Investors should be prepared to hold the shares for an extended period, with no guarantee of a future sale. Always assess your need for liquidity before investing.

SetterVC and Setter Capital do not provide due diligence, legal, tax, accounting, valuation, or investment advice. Buyers must conduct their own due diligence, including verifying ownership, transferability, legal structure, company approval, and assessing the company's prospects. SetterVC and Setter Capital do not provide advice on whether an investment is good, what price to pay, or what the best bid or ask is. SetterVC and Setter Capital may share documents in some circumstances, but it does not guarantee their accuracy or completeness. Due diligence is essential. Seek legal and investment advice as needed.

Before buying UntilLabs shares, a buyer should try to review the share class, price per share, implied valuation, transfer restrictions, ROFR process, company approval rights, seller ownership evidence, recent financing or tender-offer information, available financial information, information rights, resale restrictions, tax considerations, and expected liquidity paths. Not all information may be available for a private company. Buyers should confirm available diligence, process details, and information needs with their own legal, tax, and investment advisers.

SPVs carry risks. Examples include the need to confirm the company allows SPV-based transfers, verify that the SPV truly owns the shares or interests it claims to own, and ensure it has not sold more interests than it holds. Due diligence is essential. Seek legal and investment advice as needed.

Forward contracts carry risks. Examples include the seller refusing to transfer the shares at the future date, even if the seller owns them, the seller going bankrupt with creditors claiming the shares, or the seller committing the same shares to multiple parties. Due diligence is essential. Seek legal and investment advice as needed.

Access live market data

Sign Up

Data collected with AI, which can make mistakes. Please double-check this information.